Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial | Lancet, The | 2016 | 738 |
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial | Lancet, The | 2016 | 733 |
Single-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2 Diabetes | Cell Metabolism | 2016 | 730 |
Analysis of Past and Present Synthetic Methodologies on Medicinal Chemistry: Where Have All the New Reactions Gone? | Journal of Medicinal Chemistry | 2016 | 726 |
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer | Journal of Clinical Oncology | 2016 | 605 |
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability | Immunity | 2016 | 602 |
Alternatives to antibiotics-a pipeline portfolio review | Lancet Infectious Diseases, The | 2016 | 495 |
CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma | Cancer Cell | 2016 | 442 |
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study | Lancet Oncology, The | 2016 | 412 |
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial | Lancet Oncology, The | 2016 | 408 |
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity | Clinical Cancer Research | 2016 | 397 |
VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research | Nucleic Acids Research | 2016 | 374 |
β-Lactams and β-Lactamase Inhibitors: An Overview | Cold Spring Harbor Perspectives in Medicine | 2016 | 358 |
Mitochondria are required for pro-ageing features of the senescent phenotype | EMBO Journal | 2016 | 357 |
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action | Science Translational Medicine | 2016 | 343 |
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial | Lancet, The | 2016 | 325 |
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack | New England Journal of Medicine | 2016 | 308 |
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial | Lancet Oncology, The | 2016 | 296 |
The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis | Science Translational Medicine | 2016 | 291 |
Combenefit: an interactive platform for the analysis and visualization of drug combinations | Bioinformatics | 2016 | 286 |
A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds | Cell | 2016 | 274 |
Photoredox Mediated Nickel Catalyzed Cross-Coupling of Thiols With Aryl and Heteroaryl Iodides via Thiyl Radicals | Journal of the American Chemical Society | 2016 | 269 |
Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial | Lancet Diabetes and Endocrinology,the | 2016 | 249 |
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor | Nature | 2016 | 238 |
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study | Lancet Infectious Diseases, The | 2016 | 233 |